VSA012

DRUG3 trials

Sponsors

Bisirna Therapeutics (Suzhou) Co., Ltd., Bisirna Therapeutics Pte. Ltd.

Conditions

Healthy VolunteersParoxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria, PNH

Phase 1

A Phase I Clinical Study of VSA012 in Healthy Volunteers

Active, not recruitingNCT06766929

Bisirna Therapeutics (Suzhou) Co., Ltd.Healthy Volunteers

Start: 2025-01-20End: 2027-06-01Updated: 2026-05-04

Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria

Active, not recruitingNCT06848296

Bisirna Therapeutics Pte. Ltd.Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start: 2025-04-15End: 2027-08-31Updated: 2026-05-04

Phase 3

A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Not yet recruitingNCT07816237

Bisirna Therapeutics (Suzhou) Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria, PNH

Start: 2026-10-29End: 2029-12-31Target: 70Updated: 2026-09-11

Related Papers

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Blood2025-11-03